Welcome to our dedicated page for Ascentage Pharma Group International news (Ticker: AAPGV), a resource for investors and traders seeking the latest updates and insights on Ascentage Pharma Group International stock.
Ascentage Pharma Group International (AAPGV) is a global biopharmaceutical innovator developing targeted therapies for hematological malignancies. This dedicated news hub provides investors and medical professionals with verified updates on clinical trial progress, regulatory milestones, and strategic partnerships.
Access comprehensive coverage of AAPGV's advancements in precision medicine, including drug development timelines, research collaborations, and commercialization efforts. Our curated selection features earnings reports, scientific publications, and analysis of therapeutic pipeline developments.
Stay informed about critical updates through regularly refreshed content that maintains strict journalistic standards. All materials undergo verification to ensure accuracy in reporting complex biopharmaceutical developments and corporate announcements.
Bookmark this page for streamlined access to Ascentage Pharma's latest achievements in oncology research and evidence-based updates on their innovative treatment candidates.
Ascentage Pharma (Nasdaq: AAPG, HKEX: 6855) announced that underwriters of its U.S. initial public offering have partially exercised their over-allotment option to purchase an additional 935,144 American depositary shares (ADSs) at $17.25 per ADS. Each ADS represents four ordinary shares of the company.
Following this partial exercise, the total number of ADSs sold in the offering will increase to 8,260,144, bringing the aggregate gross proceeds to approximately $142.5 million, before deducting underwriting discounts, commissions, and other offering expenses. J.P. Morgan and Citigroup served as joint book-running managers for the offering.
Ascentage Pharma (Nasdaq: AAPG) has successfully completed its U.S. initial public offering, raising approximately $126.4 million in gross proceeds. The company offered 7,325,000 American depositary shares (ADSs) at $17.25 per ADS, with each ADS representing four ordinary shares. Trading of the ADSs commenced on the Nasdaq Global Market on January 24, 2025.
The company has granted underwriters a 30-day option to purchase up to an additional 1,098,750 ADSs at the initial offering price, less underwriting discounts and commissions. J.P. Morgan and Citigroup served as joint book-running managers for the offering.
